An Emollient Plus Balm Is Useful for the Management of Xerosis in Cancer Patients: A Real-World, Prospective, Observational, Multicenter Study

    February 2022 in “ Dermatology and therapy
    V. Vendrely, Ander Mayor-Ibarguren, Aline Stennevin, Ariadna Ortiz‐Brugués
    Image of study
    TLDR An emollient PLUS balm with ADE-G1 significantly improved skin dryness and quality of life in cancer patients with xerosis.
    In a real-world, prospective, observational, multicenter study involving 319 cancer patients with xerosis, the use of an emollient PLUS balm containing Aquaphilus dolomiae extract (ADE-G1) significantly reduced the severity of xerosis. After approximately 4 weeks of daily application, 62.7% of patients experienced a reduction in xerosis severity, with a 67.7% decrease in objective clinical signs and a 57.4% decrease in subjective clinical signs (p < 0.0001 for both). Quality of life, as measured by the Dermatology Life Quality Index (DLQI), improved by 56.6% (p < 0.0001). Over 80% of patients were rated by physicians as having "effective" or "very effective" outcomes, and overall clinical success was achieved in 73.7% of patients. The balm was well-tolerated across different types of anticancer therapies, with a trend toward higher effectiveness in patients undergoing hormonotherapy.
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results

    Related Community Posts Join

    0 / 0 results
    — no results

    Similar Research

    5 / 509 results
      Subject Index

      research Subject Index

      March 2014 in “Journal of The American Academy of Dermatology”
      The document lists various dermatology topics, treatments, and diagnostic methods.
      Dermatologic Reactions to Targeted Therapy

      research Dermatologic Reactions to Targeted Therapy

      15 citations, February 2017 in “Nursing Clinics of North America”
      Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.